Table 3.
Total of studies dealing in gray literature (total studies = 25).
| Variables * | Numbers of Studies |
|---|---|
| Gray literature (clinicaltrial.gov) | 25 |
| Included patients | |
| Only adult | 22 |
| Adult and child | 3 |
| Status of Study | |
| Closed, terminated, withdrawn, or unknown | 9 |
| Active but not recruiting; recruiting | 15 |
| Approved for marketing | 1 |
| FGFR alterations | |
| FGFR alteration (generic) | 21 |
| FGFR2 expression or overexpression | 3 |
| Type of drugs | |
| Selective inhibitors pan-FGFR | 11 |
| Non-selective TKIs | 1 |
| Phase of study | |
| Phase I | 4 |
| Phase I/II | 1 |
| Phase II | 17 |
| Phase III | 1 |
| Post-market | 1 |
| Clinical outcomes (primary) | |
| Safety a | 6 |
| Survival outcomes b | 2 |
| Efficacy a | 20 |
* Source clinicaltrial.gov; a four studies with mixed outcomes with efficacy/safety or part A and part B studies; b only one study with dedicated survival outcomes.